Hepatomegaly News and Research

RSS
Pfizer receives FDA approval for new therapy to treat adults and children with AML

Pfizer receives FDA approval for new therapy to treat adults and children with AML

New trial results show efficacy of novel enzyme-replacement therapy for genetic lipid disorder

New trial results show efficacy of novel enzyme-replacement therapy for genetic lipid disorder

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Synageva announces 12-week data from sebelipase alfa Phase I/II study on LAL Deficiency

Synageva announces 12-week data from sebelipase alfa Phase I/II study on LAL Deficiency

Biliary sludge common in dogs

Biliary sludge common in dogs

Encouraging results from Gilead’s TAF Phase 2 trial on HIV-1 infection

Encouraging results from Gilead’s TAF Phase 2 trial on HIV-1 infection

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

FDA ADAC recommends approval of Gilead’s Truvada for HIV

FDA ADAC recommends approval of Gilead’s Truvada for HIV

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

Janssen announces FDA label update approval for PREZISTA HIV tablets

Janssen announces FDA label update approval for PREZISTA HIV tablets

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

FDA approves Gilead's Complera for treatment of HIV-1 infection

FDA approves Gilead's Complera for treatment of HIV-1 infection

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010